Article ID Journal Published Year Pages File Type
9020930 Vascular Pharmacology 2005 6 Pages PDF
Abstract
The aim of this study was to investigate the role of the contractile agent on the relaxation induced by isoprenaline and the contribution of nitric oxide (NO) and cGMP to this relaxation. These studies were conducted in intact endothelium or denuded aortas contracted with the EC50 of norepinephrine (NE) or phenylephrine (Phe), and the relaxation induced by isoprenaline (non-selective β-adrenoceptor agonist) or forskolin (activator of adenylyl-cyclase) was studied. The maximum effect (Emax) and pD2 were analysed. Isoprenaline and forskolin-induced relaxation were not changed by the endothelium removal in both NE and Phe-contracted aortas. However, l-NAME reduced the relaxation induced by isoprenaline (Emax from 94.48±2.30%, n=7 to 66.17±11.73%, n=7; pD2 from 7.56±0.10 to 6.08±0.15) only in NE-contracted aortas. The pD2 of isoprenaline was also reduced by ODQ (6.57±0.13), but not the Emax. The inhibitory effects of l-NAME and ODQ were reversed by yohimbine. l-NAME, ODQ and oxyhemoglobin had no effect on the relaxation induced by isoprenaline in Phe-contracted aortas. Taken together, these results suggest that norepinephrine, a non-selective α-adrenoceptor agonist can also activate α2-adrenoceptors sensitive to yohimbine in the endothelial cells, activating the NO-synthase and cGMP production which would potentiate the relaxation induced by isoprenaline. However, this pathway is not activated with Phe, the selective α1-adrenoceptors agonist.
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Authors
, ,